Data Synthesis: Tyrosine kinase inhibitors can cause significant eye toxicity.
S
ystemic anticancer therapies can cause acute and chronic damage to the eye. Ocular toxicity is generally underestimated and underreported, and many may consider it to be a minor side effect. However, for the patient, blurred or loss of vision and other ocular symptoms can be troublesome and negatively affect quality of life. Damage to the ocular surfaces, retina, cornea, and optic nerve can be temporary or permanent. Ocular side effects are not uncommon with cytotoxic chemotherapy, but they are rarely severe or dose limiting (Huillard et al., 2014) . However, serious toxicity has been associated with molecularly targeted cancer therapies, particularly tyrosine kinase inhibitors (TKIs). This class of drug targets receptors of tyrosine kinase, an enzyme responsible for the activation of proteins involved in the growth, progression, and spread of cancer. This targeted approach is expected to have fewer side effects than more traditional cytotoxic drugs that act nonspecifically on all dividing cells of the body. Ophthalmic side effects of targeted therapies differ depending on the specific molecular targets and the area of the eye involved.
Eye Anatomy and Function
The eye can be regarded in sections, including the ocular adnexa, anterior segment of the eye, and the posterior segment (see Figure 1) . The adnexa of the eye includes the eyelids, eyelashes, lacrimal system, and meibomian glands. The eyelids are folds of muscular tissue that serve to protect the eyeball. The skin on the outer surface of the eyelids is very thin, with little subcutaneous
